Bridging Experience With Eptifibatide After Stent Implantation

Area of Science:

• Cardiology
• Pharmacology
• Surgical Management

Background:

• Patients with intracoronary stents often need surgery within a year, requiring antiplatelet therapy interruption.
• This interruption increases the risk of stent thrombosis.
• Intravenous glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa) like eptifibatide can bridge high-risk patients perioperatively.

Purpose of the Study:

• To describe antiplatelet therapy management and outcomes.
• To evaluate perioperative bridging with eptifibatide in patients within one year of stent implantation.

Main Methods:

• Retrospective analysis of 18 patients bridged with eptifibatide before surgery.
• Oral P2Y12-receptor antagonist to eptifibatide bridging.
• Outcome measures included thromboembolic events, stent thrombosis, and bleeding within specific timeframes.

Main Results:

• No thromboembolic events or stent thrombosis occurred in the 18 patients.
• One major and one minimal bleeding event were observed.
• Significant variability in perioperative antiplatelet management was noted, including dosing and timing.

Conclusions:

• Perioperative bridging with intravenous GPIIb/IIIa inhibitors appears feasible for patients with recent stenting.
• Optimal strategies for managing antiplatelet therapy in this population require further investigation.